<DOC>
	<DOCNO>NCT00388583</DOCNO>
	<brief_summary>As result safety immunogenicity data generate earlier dose-ranging study , present formulation select development elderly . Primary Objective : To compare immunogenicity subject receive investigational Fluzone subject receive standard Fluzone® . Secondary Objectives : Immunogenicity : To describe immunogenicity subject receive investigational Fluzone standard Fluzone® . Safety : To evaluate describe safety profile investigational Fluzone term solicited- unsolicited adverse event serious adverse event post-vaccination .</brief_summary>
	<brief_title>Study Inactivated , Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Orthomyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged ≥ 65 year day vaccination . Informed consent form sign . Medically stable ( Subjects may underlie illness hypertension , diabetes , ischemic heart disease , congestive cardiac disorder hypothyroidism , long symptoms/signs control ) . Able attend schedule visit comply trial procedure . Systemic hypersensitivity egg , chicken protein , vaccine component , history lifethreatening reaction standarddose Fluzone® vaccine vaccine contain substance ( list vaccine component include Investigator 's Brochure ) . Congenital history acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month . Systemic corticosteroid therapy follow : Continuous use dosage equivalent &gt; 15 mg/day oral prednisone 90 day precede vaccination Sporadic use dose &gt; 40 mg/day oral prednisone &gt; 14 day 90 day precede vaccination . Note : Use topical inhalant corticosteroid acceptable . Neoplastic disease hematologic malignancy ( except localize skin prostate cancer stable time vaccination absence therapy , well subject history neoplastic disease diseasefree ≥ 5 year ) . Current abuse alcohol drug addiction may interfere subject 's ability comply trial procedure . Receipt blood bloodderived product past 3 month . Vaccination influenza past 6 month . Any vaccination 4 week precede trial vaccination . Vaccination plan 4 week follow trial vaccination . Participation another clinical trial 4 week precede trial vaccination . Planned participation another clinical trial present trial period . Concomitant participation observational trial ( involve drug , vaccine , medical device ) acceptable . Chronic illness stage could interfere trial conduct completion . Known current HIV , hepatitis B ( HBsAg ) hepatitis C infection seropositivity . Known thrombocytopenia bleed disorder contraindicate IM vaccination . Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent . Acute illness febrile illness temperature ≥ 38.0°C [ 100.4°F ] ) 72 hour day inclusion . Received antibiotic therapy within 72 hour precede trial vaccination . Received allergy shot 7day period precede trial vaccination and/or schedule receive allergy shot 7day period trial vaccination . Any condition , opinion investigator would pose health risk participant .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Orthomyxoviruses</keyword>
	<keyword>Inactivated Split-virion influenza vaccine</keyword>
	<keyword>Elderly .</keyword>
</DOC>